EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis Integrating Randomized Controlled Trials and Prospective Evidence

Meng‐Fei Dai, Gao‐Wei Chong, Wen‐Xiu Xin, Si‐Si Kong, Jun‐Feng Zhu, Li‐Ke Zhong, Gao‐Qi Xu, Xiang‐Yu Jin, Chao‐Neng He, Ting‐Ting Wang, Xiu‐Fang Mi, Liping Luo, Zhu‐Jin Song, Hai‐Ying Ding, Luo Fang

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-11 · 45 (11) · 764-773

DOI: 10.1002/phar.70075 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Although randomized controlled trials (RCTs) have established evidence regarding thromboembolic risks of thrombopoietin receptor agonists (TPO‐RAs) in immune thrombocytopenia (ITP) during short‐term follow‐up, the long‐term risks remain uncertain. This meta‐analysis integrates data from prospective studies and RCTs to provide a comprehensive evaluation of thromboembolic risks associated with TPO‐RA therapy. Methods PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 23, 2025 for RCTs and prospective studies reporting thromboembolic events in patients treated with TPO‐RAs. The primary outcome was the risk of any thromboembolism. Subgroup analyses separately assessed the incidence of venous and arterial thrombosis. Short‐term (≤ 6 months) evidence was derived from RCTs, while long‐term (6–12 months and > 12 months) evidence was supplemented by prospective studies. Data from RCTs were analyzed using the Peto odds ratio (OR) with 95% confidence intervals (CIs), and data from prospective studies were pooled to calculate the incidence of thromboembolic events. Results The analysis included 12 RCTs (involving 1530 patients) and 11 prospective studies (involving 1820 patients). TPO‐RAs significantly increased thromboembolic risk compared to placebo in the short‐term (0.72% vs. 0.23%, Peto OR = 3.25, 95% CI = 1.11–9.51, p = 0.03). Pooled results from prospective studies demonstrated thromboembolism incidence of 3.84% at 6 to 12 months and 5.59% beyond 12 months of treatment with TPO‐RAs. The reported incidence of arterial thrombosis increased from 0.14% (≤ 6 months) to 1.51% (6–12 months), and further to 4.2% (> 12 months). Whereas the reported incidence of venous thrombosis increased from 0.18% (≤ 6 months) to 2.50% (6–12 months), and plateaued at 2.55% beyond 12 months. Conclusion This analysis demonstrates that TPO‐RAs therapy increases the risk of thromboembolism, with the risk of arterial events becoming particularly pronounced during long‐term use. These findings highlight the need for individualized risk assessment and vigilant monitoring in patients receiving TPO‐RAs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →